Epizyme (NASDAQ:EPZM) has announced its Q3 2020 financial results reporting 55% QoQ growth in net TAZVERIK® revenue to $3.4 million.
TAZVERIK generated $3.4 million in Q3
Robert Bazemore, the company’s CEO, said that this year has been exciting for the company which is executing its TAZVERIK launches well. This is despite the unprecedented challenges the pandemic has paused on FL patients’ access top physicians and Epizyme’s access to customers. Bazemore said that despite the impact of the pandemic on initial uptake in FL, the company is still reaching both FL and ES patients based on its label and TAZVERIK value proposition remains unchanged.
TAZVERIK® execution in the US for refractory/relapsed epithelioid sarcoma (ES) and follicular lymphoma progressed well in Q. the company posted product revenue of $3.4 million which was mainly due to the FDA approval of TAZVERIK in FL in June. In Q3, the pandemic continued to impact physician visits for FL patients; the new patient starts in all treatment lines and the ability of the company’s field agents to access FL prescribers. The company indicated it had seen a month over month increase in New TAZVERIK prescriptions in FL given for EZH2 mutation and wild-type patients. Equally, FL and ES payor coverage are in line with the TAZVERIK label, and the company continues to implement its commercial strategy to the pandemic to boost TAZVERIK adoption.
Epizyme conducting TAZVERIK confirmatory studies
The company published its phase 2 data for the study evaluating TAZVERIK in ES and relapsed/refractory FL treatment in The Lancet Oncology journal. The study supported expedited FDA approval for both indications in 2020. Enrolment in the safety run-in cohorts in the company’s two confirmatory TAZVERIK studies is on track to complete at the end of this year followed by the commencement of efficacy parts in early 2021. The ES confirmatory study is evaluating TAZVERIK combination with doxorubicin versus doxorubicin plus placebo as a frontline ES treatment. The FL confirmatory TAZVERIK study is evaluating its combination with revlimid® plus rituxan® (R2) versus R2 plus placebo as second-line FL treatment.